Business
S&P upgrades Hikma to ‘BBB’
S&P upgrades Hikma to ‘BBB’.
About this update from Hikma Pharmaceuticals Plc
[{"type":"text","content":"\n\nS&P upgrades Hikma Pharmaceuticals PLC and its Senior Notes to 'BBB' on continued good business momentum; outlook stable\n \nLondon, 8 May 2025 - S&P has today announced that it has raised its long-term issuer credit rating on Hikma Pharmaceuticals PLC (Hikma, Company) and its $500 million notes outstanding due July 9, 2025, issued out of Hikma Finance USA LLC, to 'BBB' from 'BBB-' with a stable outlook. S&P said its rating action reflects Hikma's good business momentum and ability to maintain healthy growth prospects and stable credit metrics. \n \nKhalid Nabilsi, CFO of Hikma said: \"I am pleased that S&P have upgraded Hikma today, strengthening our investment grade rating and confirming our solid market position as well as our track record of profitability and cash generation.\"\n \n-- ENDS --\nEnquiries:\nHikma (Investors) \n\n\n\n\nSusan Ringdal\nEVP, Strategic Planning and Global Affairs\n\n\n+44 (0)20 7399 2760/ +44 (0)7776 477050\n\n\n\n\nGuy Featherstone\nDirector, Investor Relations \n\n\n+44 (0)20 3892 4389/ +44 (0)7795 896738\n\n\n\n\nLayan Kalisse\nSenior Associate, Investor Relations\n\n\n+44 (0)20 7399 2788/ +44 (0)7970 709912\n\n\n\n\n \nFTI Consulting (Media) \nCiara Martin\n\n\n \n \n \n+44 (0)7779 775979\n\n\n\n\n \n \n \n \nAbout Hikma\nHikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB/stable S&P and BBB-/positive Fitch)\n \nHikma helps put better health within reach every day for millions of people around t...